Luiza Milaré
Research Subjects
Luiza Milaré has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Seber
Hospital Samaritano Higienópolis – São Paulo (SP), Brazil
2 shared publications - Carla Nolasco Monteiro Breviglieri
Hospital Samaritano de São Paulo – São Paulo (SP), Brazil
2 shared publications - Cilmara Kuwahara
Hospital Pequeno Príncipe – Curitiba (PR), Brazil
2 shared publications - Adriana Martins de Sousa
Universidade Federal do Rio de Janeiro – Instituto de Puericultura e Pediatria Martagão Gesteira – Rio de Janeiro (RJ), Brazil
1 shared publication - Ana Carolina Ribeiro Correa
Universidade Federal de São Paulo – Department of Pediatric Oncology and Bone Marrow Transplant – Pediatric Oncology Institute – São Paulo (SP), Brazil
1 shared publication - Ana Luiza de Melo Rodrigues
Hospital Erastinho – Curitiba (PR), Brazil|Universidade Federal do Paraná – Faculdade de Medicina – Departamento de Clínica Médica – Curitiba (PR), Brazil
1 shared publication
Latest Publications
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Consensus in stem cell transplantation for pediatric lymphomas
Lymphomas are the third most common childhood cancer in Brazil. Management is predicated on precise diagnosis and staging through clinical, pathological, molecular, and radiological evaluation. Although the prognosis for pediatric non-Hodgkin and Hodgkin lymphoma has improved markedly, relapsed or refractory cases remain a clinical challenge. For these patients, aggressive chemotherapy followed by autologous or allogeneic hematopoietic cell transplantation serves as a vital salvage strategy. The Pediatric Group of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy has revised its current consensus, providing updated recommendations for indications and conditioning protocols. This revision also includes the assessment of new therapeutic strategies, including immunotherapy and CAR-T cell therapy, for eligible patients.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessConsensus in stem cell transplantation for pediatric lymphomas
Lymphomas are the third most common childhood cancer in Brazil. Management is predicated on precise diagnosis and staging through clinical, pathological, molecular, and radiological evaluation. Although the prognosis for pediatric non-Hodgkin and Hodgkin lymphoma has improved markedly, relapsed or refractory cases remain a clinical challenge. For these patients, aggressive chemotherapy followed by autologous or allogeneic hematopoietic cell transplantation serves as a vital salvage strategy. The Pediatric Group of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy has revised its current consensus, providing updated recommendations for indications and conditioning protocols. This revision also includes the assessment of new therapeutic strategies, including immunotherapy and CAR-T cell therapy, for eligible patients.
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Consensus in stem cell transplantation for pediatric solid tumors
Solid tumors in the pediatric population are preferred treated in clinical national or international protocols, in which the work of pediatric oncology cooperative groups guides the therapeutic standards and advancements. The role of high-dose chemotherapy (HDC) and hematopoietic cell transplant (HCT) in the pediatric population is usually reserved for patients or subgroups of patients who have diseases with poor prognosis and sometimes are refractory to the best available treatment, in combination to conventional chemotherapy, surgical procedure, and radiation. The Pediatric Group of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy has revised its current consensus, providing updated recommendations for indications and conditioning protocols. This updated guidance emphasizes that, while HDC/HCT is an important tool for specific high-risk malignancies, several tumors continue to have no indication for autologous transplantation based on current evidence.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessConsensus in stem cell transplantation for pediatric solid tumors
Solid tumors in the pediatric population are preferred treated in clinical national or international protocols, in which the work of pediatric oncology cooperative groups guides the therapeutic standards and advancements. The role of high-dose chemotherapy (HDC) and hematopoietic cell transplant (HCT) in the pediatric population is usually reserved for patients or subgroups of patients who have diseases with poor prognosis and sometimes are refractory to the best available treatment, in combination to conventional chemotherapy, surgical procedure, and radiation. The Pediatric Group of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy has revised its current consensus, providing updated recommendations for indications and conditioning protocols. This updated guidance emphasizes that, while HDC/HCT is an important tool for specific high-risk malignancies, several tumors continue to have no indication for autologous transplantation based on current evidence.
- Open Access
- 9 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Consensus in infection complications
Infectious complications remain a leading cause of morbidity and mortality in pediatric recipients of hematopoietic stem cell transplantation (HSCT). In Brazil, the access to effective therapies for multidrug-resistant bacterial, invasive fungal, and viral infections is frequently limited in the public healthcare system (SUS), posing significant challenges to optimal clinical management. This consensus-based review, endorsed by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation, focuses on selected pediatric infectious complications in HSCT for which access to appropriate antimicrobial therapy remains particularly restricted. We summarize recommended antimicrobial agents for multidrug-resistant bacterial infections, invasive fungal diseases, and viral infections, highlighting discrepancies between evidence-based treatment strategies and drug availability in the SUS.
- 9 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessConsensus in infection complications
Infectious complications remain a leading cause of morbidity and mortality in pediatric recipients of hematopoietic stem cell transplantation (HSCT). In Brazil, the access to effective therapies for multidrug-resistant bacterial, invasive fungal, and viral infections is frequently limited in the public healthcare system (SUS), posing significant challenges to optimal clinical management. This consensus-based review, endorsed by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation, focuses on selected pediatric infectious complications in HSCT for which access to appropriate antimicrobial therapy remains particularly restricted. We summarize recommended antimicrobial agents for multidrug-resistant bacterial infections, invasive fungal diseases, and viral infections, highlighting discrepancies between evidence-based treatment strategies and drug availability in the SUS.
- Open Access
- 8 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia
Acute myeloid leukemia (AML) accounts for 15% to 20% of pediatric acute leukemia cases. Treatment failure is influenced by both genetic risk and response to therapy1,2,3,4. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity5. Improved survival outcomes are associated with comprehensive strategies that combine intensive chemotherapy, effective supportive care, and hematopoietic stem cell transplantation (HCT), adjusted to the relapse risk profile of each patient6-10. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML, to provide evidence-based guidance for the appropriate management of this disease. This is the 2025 update of the previously guideline.
- 8 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessHematopoietic stem cell transplantation for pediatric acute myeloid leukemia
Acute myeloid leukemia (AML) accounts for 15% to 20% of pediatric acute leukemia cases. Treatment failure is influenced by both genetic risk and response to therapy1,2,3,4. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity5. Improved survival outcomes are associated with comprehensive strategies that combine intensive chemotherapy, effective supportive care, and hematopoietic stem cell transplantation (HCT), adjusted to the relapse risk profile of each patient6-10. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML, to provide evidence-based guidance for the appropriate management of this disease. This is the 2025 update of the previously guideline.
- Open Access
- 3 December 2018
- Published by Pontifical Catholic University of Sao Paulo (PUC-SP) in Revista da Faculdade de Ciências Médicas de Sorocaba
- Vol. 20 (3) , 187
Glioma de tronco cerebral
- 3 December 2018
- Published by Pontifical Catholic University of Sao Paulo (PUC-SP) in Revista da Faculdade de Ciências Médicas de Sorocaba
- Vol. 20 (3) , 187
Open AccessGlioma de tronco cerebral